Where Will Exelixis, Inc. (EXEL) Stock Go Next After It Has Fallen 10.35% in a Week?

Exelixis, Inc. (EXEL) stock is lower by 10.35% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Exelixis, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on EXEL!

See Full EXEL Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With EXEL Stock Today?

Exelixis, Inc. (EXEL) stock is trading at $17.75 as of 11:53 AM on Thursday, May 19, a loss of -$1.74, or -8.93% from the previous closing price of $19.49. The stock has traded between $17.55 and $19.48 so far today. Volume today is below average. So far 882,769 shares have traded compared to average volume of 2,279,378 shares. To screen for more stocks like Exelixis, Inc. click here.

More About Exelixis, Inc.

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Click Here to get the full Stock Report for Exelixis, Inc. stock.